Juno Pharmaceuticals-B (02142.HK) announced its interim report for 2024, with revenue of $23,701 thousand, a 42.2% decrease compared to the same period last year. Sales cost $1,185 thousand, other income and gains $3,488 thousand. Research and development cost $13,095 thousand, administrative expenses $7,917 thousand, and financing cost $1,559 thousand. Net profit for the period was $1,397 thousand, and earnings per share (basic and diluted) were $0.00. As of June 30, 2024, cash and cash equivalents were $183,038 thousand, total assets were $219,706 thousand, total liabilities were $96,899 thousand, and total equity was $122,807 thousand. No dividends were distributed by the company during the reporting period. There were no significant changes in the company's shares after the reporting period.

Juno Pharmaceuticals-B (02142.HK) announced its interim report for 2024, with revenue of $23,701 thousand, a 42.2% decrease compared to the same period last year. Sales cost $1,185 thousand, other income and gains $3,488 thousand. Research and development cost $13,095 thousand, administrative expenses $7,917 thousand, and financing cost $1,559 thousand. Net profit for the period was $1,397 thousand, and earnings per share (basic and diluted) were $0.00. As of June 30, 2024, cash and cash equivalents were $183,038 thousand, total assets were $219,706 thousand, total liabilities were $96,899 thousand, and total equity was $122,807 thousand. No dividends were distributed by the company during the reporting period. There were no significant changes in the company's shares after the reporting period.